ArticleJournal of radiation research2019
Analysis of the high-dose-range radioresistance of prostate cancer cells, including cancer stem cells, based on a stochastic model.
Article in Journal of radiation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Generality Assessment of a Model Considering Heterogeneous Cancer Cells for Predicting Tumor Control Probability for Stereotactic Body Radiation Therapy Against Non-Small Cell Lung Cancer.Advances in radiation oncology · 2024Article
- DNA‑PKcs phosphorylation specific inhibitor, NU7441, enhances the radiosensitivity of clinically relevant radioresistant oral squamous cell carcinoma cells.Biomedical reports · 2023Article
- Application of Gold Nanoparticles as Radiosensitizer for Metastatic Prostate Cancer Cell Lines.International journal of molecular sciences · 2023Article
- A feasibility study of the therapeutic application of a mixture ofMedical physics · 2022Article
- Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.Cancers · 2022Review
- Tumor radioresistance caused by radiation-induced changes of stem-like cell content and sub-lethal damage repair capability.Scientific reports · 2022Article
- Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2021Article
- Epigenetic mechanisms underlying prostate cancer radioresistance.Clinical epigenetics · 2021Review
- 4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication.Scientific reports · 2021Article
- Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.Molecular cancer therapeutics · 2021Article
- Low Dose Combined Treatment with Ultraviolet-C and Withaferin a Enhances Selective Killing of Oral Cancer Cells.Antioxidants (Basel, Switzerland) · 2020Article
- Conventional Treatment of Glioblastoma Reveals Persistent CD44Molecular neurobiology · 2020Article
- CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer.Cells · 2020Review
- Article
- Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In radiotherapy, cancer stem cells (CSCs) are well recognized as one of the radioresistant cell types. Even in a small subpopulation, CSCs may have an influence on tumor control probability, represented by cell killing after irradiation. However, the relationship between the percentage content of CSCs and the cell survival dose-response curve has not yet been quantitatively clarified. In this study, we developed a cell-killing model for two cell populations (CSCs and progeny cells) to predict the surviving fractions, and compared it with the conventional linear-quadratic (LQ) model. Three prostate cancer cell lines (DU145, PC3 and LNCaP) were exposed to X-rays at doses ranging from 0 to 10 Gy. After the irradiation, we performed clonogenic survival assays to generate the cell survival curves, and carried out flow-cytometric analyses to estimate the percentage content of CSCs for each cell line. The cell survival curves for DU145 cells and PC3 cells seemed not to follow the conventional LQ model in the high dose range (>8 Gy). However, the outputs of the developed model agreed better with the experimental cell survival curves than those of the LQ model. The percentage content of CSCs predicted by the developed model was almost coincident with the measured percentage content for both DU145 cells and PC3 cells. The experiments and model analyses indicate that a small subpopulation of radioresistant CSCs has lower radiosensitivity in the high-dose range, which may lessen the clinical outcome for patients with prostate cancer after high-dose radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.